P-glycoprotein expression in multidrug resistance.

  • 104 Pages
  • 3.38 MB
  • English
The Physical Object
Pagination104 leaves
ID Numbers
Open LibraryOL14743891M

Sugawara I, Kataoka I, Morishita Y, Hamada H, Tsuruo T, Itoyama S, Mori S. Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK Cancer Res.

Apr 1; 48 (7)–Cited by: differential expression of these genes could alter the stoichiometry of individual Pgp isoforms in the cell P-GLYCOPROTEIN AND MULTIDRUG RESISTANCE Figure 1. Model for transmembrane topology of P-glycoprotein. This illustration is based on the human mdrl sequence (9); however, all P glycoproteins share a very similar by: The multidrug resistant (MDR) phenotype is a well‐studied subject that has been recognized as a determinant underlying specific types of drug resistance in human cancer.

only in human renal cell carcinoma cell lines which have an increased expression of PKC with concomitant increased expression of P‐glycoprotein in lines with an Cited by: Multidrug resistance in cancer is linked to expression of the P-glycoprotein multidrug transporter (Pgp, ABCB1), which exports many structurally diverse compounds from cells.

P-glycoprotein (PGP), multidrug resistance-related protein (MRP) and lung resistance-related protein (LRP) expression were frequently observed in neoplastic cells of all carcinoma types, and.

P-glycoprotein is a transmembrane protein thought to function as an efflux pump to detoxify cells. It is associated with multidrug resistance in laboratory systems and has recently been found P-glycoprotein expression in multidrug resistance.

book human tumors associated with in vitro and clinical drug resistance. We used an immunohistochemical method employing two monoclonal antibodies, JSB-1 and C, to detect expression of P-glycoprotein.

In Multi-Drug Resistance in Cancer, leading researchers in the field provide comprehensive and up-to-date reviews of multidrug resistance mechanisms, from over-expression of ATP-binding cassette drug transporters such as P-glycoprotein, multidrug resistance-associated proteins, and breast cancer resistance protein, to the drug ratio-dependent.

Figure 1. High ABCB1 mRNA is associated with resistance to microtubule-targeting agents in cell lines.A, P-gp expression strongly associates with lack of response to vinblastine (P = ) and paclitaxel (P = 1E−29) in a panel of N = solid cancer cell lines ().Gene expression levels are color-coded from red (high expression) to green (low expression), with black indicating mean expression.

P-glycoprotein, a transmembrane ATP-dependent efflux pump encoded by the mdr1 gene, 1 has a central role in multidrug resistance in vitro, 2 and its clinical relevance is under investigation.

3,4. P-glycoprotein P-glycoprotein expression in multidrug resistance. book or multidrug resistance protein 1 (Mdr1) is a member of the ATP binding cassette (ABC) superfamily of transmembrane transport proteins and in the dog is encoded by the gene Mdr1.

P-gp is an important drug efflux transporter that has a significant impact on the gastrointestinal absorption, distribution, metabolism. Daniel G. Gerardi, Mirela Tinucci-Costa, Ana Carolina T.

Silveira, Juliana V. Moro, Expression of P-glycoprotein, multidrug resistance-associated protein, glutathione-S-transferase pi and p53 in canine transmissible venereal tumor, Pesquisa Veterinária Brasileira, /SX, 34, 1, (), ().

Hypoxia in tumors is generally associated with chemoresistance and radioresistance. However, the correlation between the heterodimeric hypoxia‐inducible factor‐1 (HIF‐1) and the multidrug resistance transporter P‐glycoprotein (P‐gp) has not been investigated. Herein, we demonstrate that with increasing size of DU‐ prostate multicellular tumor spheroids the pericellular oxygen.

Download P-glycoprotein expression in multidrug resistance. EPUB

P-glycoprotein 1 (permeability glycoprotein, abbreviated as P-gp or Pgp) also known as multidrug resistance protein 1 (MDR1) or ATP-binding cassette sub-family B member 1 (ABCB1) or cluster of differentiation (CD) is an important protein of the cell membrane that pumps many foreign substances out of cells.

More formally, it is an ATP-dependent efflux pump with broad substrate. This phenomenon is known as multidrug resistance (multidrug resistance, MDR). The membrane transporters play a role in the absorption, distribution and elimination of metabolic products, of ions and of most drugs.

The membrane transporters include a variety of membrane proteins with different structures and functions, such as, for example Format: Paperback. Rosenberg MF, Callaghan R, Ford RC, Higgins CF. Structure of the multidrug resistance P-glycoprotein to nm resolution determined by electron microscopy and image analysis.

J Biol Chem. ; – Ruetz S, Gros P. Functional expression of P-glycoprotein in secretory vesicles. J Biol Chem. ; – Leith CP, Kopecky KJ, Chen IM et al () Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study.

Blood – PubMed Google Scholar. This compound altered the expression of P-glycoprotein (P-gp, ABCB1), multidrug resistance-associated protein 1 (MRP1, ABCC1) and breast cancer resistance protein (BCRP, ABCG2).

2,3-Dehydrosilybin AB exhibited the most effective inhibition of acetylcholinesterase activity.

Description P-glycoprotein expression in multidrug resistance. PDF

We can clearly postulate that silybin derivatives could serve well as. The multidrug transporter, P-glycoprotein, actively mediates cholesterol redistribution in the cell membrane. Proc. Natl Acad. Sci. USA 99(16), – ().Crossref, Medline, CAS, Google Scholar; 53 Troost J, Lindenmaier H, Haefeli WE, Weiss J.

Modulation of cellular cholesterol alters P-glycoprotein activity in multidrug-resistant. Relationship between P-glycoprotein and multidrug resistance in refractory regulatory mechanism and influence of TNF-α on the P-glycoprotein Jing Wang1*, Lingqiang Chen2*, Qin Li1, Jinwei Chen3, Jing Tian3, Fen Li 3, Xi Xie, Jinfeng Du3, Ni Mao3 1Department of Rheumatology and Immunology, The First People’s Hospital of Yunnan Province, Kunming.

RESEARCH Open Access The effects of ultrasound exposure on P-glycoprotein-mediated multidrug resistance in vitro and in vivo Chixiong Huang1†, Senlin Huang†, Hairui Li1, Xinzhong Li1, Bing Li1, Lintao Zhong1, Junfeng Wang2, Meishen Zou1, Xiang He1, Hao Zheng1, Xiaoyun Si1, Wangjun Liao3, Yulin Liao1, Li Yang4* and Jianping Bin1* Abstract.

Multidrug resistance (MDR) to chemotherapeutic drugs is the main cause of chemotherapy failure in cancer treat - ment, and it generally results from expression of ATP-dependent efflux pump P-glycoprotein (P-gp).

MDR reversal agents typically act by inhibiting the drug efflux activity of P-gp, thereby increasing intracellular drug levels.

Overexpression of Pgp was linked to multidrug resistance (MDR) in mammalian cell lines and human cancers, evoking intense interest first from molecular and cell biologists, and later, when purified Pgp became available, from biochemists and biophysicists.

Two drug-resistant sublines, CP and RT, were simultaneously selected by cis-diamminedichloroplatinum (CDDP) from the human colon carcinoma cell line LoVo by the conventional method of continuous drug exposure. The 2 sublines differed in morphology, growth kinetics and pattern of gene expression.

P-glycoprotein (P-gp) is a member of the superfamily of ABC transporters which transport various molecules across cellular membranes, and is highly expressed in the intestinal epithelium [].

P-gp is an energy-dependent efflux pump driven by ATP hydrolysis [ ]. MULTIDRUG resistance in chemotherapy for cancer is characterized by increased expression of P-glycoprotein, a conserved kd plasma membrane protein homologous to.

We examined the levels of expression of the multidrug resistance-associated protein (MRP) gene quantified by Northern blot analysis in comparison with those of the MDR1 gene determined by reverse transcription-polymerase chain reaction (RT-PCR) in non-small-cell lung cancer (NSCLC) specimens [59 adenocarcinoma (Ad), 40 squamous cell carcinoma (Sq), four large cell carcinoma (La) and one.

P‐glycoprotein (P‐gp, multidrug resistance 1 (MDR1)) overexpression confers multidrug resistance to cancer cells, and P‐gp in cell lines transfected with MDR1 or selected with chemotherapeutics significantly affect the anticancer drug efficacy.

Although human cancer cell line panels consisting of defined tumor cell lines expressing endogenous P‐gp have been used to screen. Ovarian Cancer Renal Cell Carcinoma Multidrug Resistance Multi Drug Resistance Blast Crisis These keywords were added by machine and not by the authors.

This process is experimental and the keywords may be updated as the learning algorithm improves.

Details P-glycoprotein expression in multidrug resistance. EPUB

Overexpression of ATP-dependent efflux pump P-glycoprotein (P-gp) is the main cause of multidrug resistance (MDR) and chemotherapy failure in cancer treatment. Inhibition of P-gp-mediated drug efflux is an effective way to overcome cancer drug resistance.

One reason for the failure of chemotherapy in the treatment of advanced cancers may be the outgrowth of multidrug-resistant tumour cells1–5. Multidrug resistance has been modelled in numerous. Vilaboa NE, Galán A, Troyano A, de Blas E, Aller PJ. Regulation of multidrug resistance 1 (MDR1)/P-glycoprotein gene expression and activity by heat-shock transcription factor 1 (HSF1).

J Biol Chem ; (32): Expression of P-glycoprotein (P-gp), the multidrug resistance (MDR) 1 gene product, can lead to MDR in tumors. However, the physiological role of P-gp in normal tissues is not well understood.

Previous studies on multidrug-resistant cells have suggested changes in membrane fluidity and membrane potential associated with P-gp expression, but interpretation of these studies is difficult, because.Cordon-Cardo, O'Brien, Boccia et al.

"Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues". Journal of Histochemistry and Cytochemistry, Vol. 38, No. 9, pp. – (September ) Cordon-Cardo. "Mutations of cell cycle regulators.

Biological and clinical implications for human neoplasia".